Answers are grounded in this paper and cite their sources.
Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative approach for treating a range of health challenges. Accelerated by the success of mRNA-lipid nanoparticle (LNP) vaccines during the COVID-19 pandemic, this platform holds promise beyond immunisation for the transient expression of therapeutic proteins in targeted tissues. Despite this promise, non-invasive delivery of mRNA-encoded cargo to the brain remains a challenge, as most peptide drugs do not pass the blood-brain barrier. Here, we present the development of an intranasal mRNA-LNP therapeutic that drives production of neurotrophic factors in the nasal epithelium and delivery of the encoded protein to the brain. As a proof of concept, we demonstrate that intranasal delivery of mRNA encoding the neurogenic factor BDNF (Brain Derived Neurotrophic Factor) enhances memory performance in both aged mice and a transgenic mouse model of Alzheimer's disease. This approach offers a promising platform for delivering therapeutic proteins to the brain and opens new avenues for treating age-related and neurodegenerative disorders.
No takes yet. Share an insight, caveat, or question.
Bergamasco et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: